PURPOSE: To examine associations among methotrexate pharmacodynamics, neuroimaging, and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy-only protocol. PATIENTS AND METHODS: This longitudinal study linked pharmacokinetic assays collected during therapy to neurocognitive and brain imaging outcomes during long-term follow-up. A total of 218 (72.2%) of 302 eligible long-term survivors were recruited for outcome studies when they were more than 5 years post-diagnosis and older than 8 years of age. At long-term follow-up, survivors were an average of 13.8 years old and 7.7 years from diagnosis, and 51% were male. Neurocognitive testing, functional magnetic resonance imaging (MRI) during an executive function task, and structural MRI with diffusion tensor imaging were conducted. Generalized linear models were developed to identify predictors, and models were adjusted for age at diagnosis, sex, and parent education. RESULTS: Intelligence was within normal limits (mean, 98; standard deviation, 14) compared with population expectations (mean, 100; standard deviation, 15), though measures of executive function, processing speed, and memory were less than population means (all P < .02 after correction for false discovery rates). Higher plasma concentration of methotrexate was associated with a poorer executive function score (P < .02). Higher plasma methotrexate was also associated with higher functional MRI activity, with thicker cortices in dorsolateral prefrontal brain regions, and with white matter microstructure in the frontostriatal tact. Neurocognitive impairment was associated with these imaging findings as well. Associations did not change after adjustment for age or dose of leucovorin rescue. CONCLUSION: Survivors of childhood acute lymphoblastic leukemia treated on contemporary chemotherapy-only protocols demonstrate executive dysfunction. A higher plasma concentration of methotrexate was associated with executive dysfunction as well as with a thicker cortex and higher activity in frontal brain regions, regions often associated with executive function.
PURPOSE: To examine associations among methotrexate pharmacodynamics, neuroimaging, and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy-only protocol. PATIENTS AND METHODS: This longitudinal study linked pharmacokinetic assays collected during therapy to neurocognitive and brain imaging outcomes during long-term follow-up. A total of 218 (72.2%) of 302 eligible long-term survivors were recruited for outcome studies when they were more than 5 years post-diagnosis and older than 8 years of age. At long-term follow-up, survivors were an average of 13.8 years old and 7.7 years from diagnosis, and 51% were male. Neurocognitive testing, functional magnetic resonance imaging (MRI) during an executive function task, and structural MRI with diffusion tensor imaging were conducted. Generalized linear models were developed to identify predictors, and models were adjusted for age at diagnosis, sex, and parent education. RESULTS: Intelligence was within normal limits (mean, 98; standard deviation, 14) compared with population expectations (mean, 100; standard deviation, 15), though measures of executive function, processing speed, and memory were less than population means (all P < .02 after correction for false discovery rates). Higher plasma concentration of methotrexate was associated with a poorer executive function score (P < .02). Higher plasma methotrexate was also associated with higher functional MRI activity, with thicker cortices in dorsolateral prefrontal brain regions, and with white matter microstructure in the frontostriatal tact. Neurocognitive impairment was associated with these imaging findings as well. Associations did not change after adjustment for age or dose of leucovorin rescue. CONCLUSION: Survivors of childhood acute lymphoblastic leukemia treated on contemporary chemotherapy-only protocols demonstrate executive dysfunction. A higher plasma concentration of methotrexate was associated with executive dysfunction as well as with a thicker cortex and higher activity in frontal brain regions, regions often associated with executive function.
Authors: Kevin R Krull; Deepa Bhojwani; Heather M Conklin; Deqing Pei; Cheng Cheng; Wilburn E Reddick; John T Sandlund; Ching-Hon Pui Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Martin Dresler; Lisa Genzel; Michael Kluge; Petra Schüssler; Frank Weber; Marcus Rosenhagen; Axel Steiger Journal: Psychoneuroendocrinology Date: 2010-03-11 Impact factor: 4.905
Authors: Brenda J Spiegler; Kimberly Kennedy; Ronnen Maze; Mark L Greenberg; Sheila Weitzman; Johann K Hitzler; Paul C Nathan Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: Kevin R Krull; Tara M Brinkman; Chenghong Li; Gregory T Armstrong; Kirsten K Ness; Deo Kumar Srivastava; James G Gurney; Cara Kimberg; Matthew J Krasin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: Hauke Rühs; Achim Becker; Anne Drescher; John C Panetta; Ching-Hon Pui; Mary V Relling; Ulrich Jaehde Journal: PLoS One Date: 2012-09-25 Impact factor: 3.240
Authors: N D Sabin; Y T Cheung; W E Reddick; D Bhojwani; W Liu; J O Glass; T M Brinkman; S N Hwang; D Srivastava; C-H Pui; L L Robison; M M Hudson; K R Krull Journal: AJNR Am J Neuroradiol Date: 2018-09-13 Impact factor: 3.825
Authors: Slim Fellah; Yin T Cheung; Matthew A Scoggins; Ping Zou; Noah D Sabin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Robert J Ogg; Kevin R Krull Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Nicholas S Phillips; Yin Ting Cheung; John O Glass; Matthew A Scoggins; Wei Liu; Robert J Ogg; Daniel A Mulrooney; Ching-Hon Pui; Leslie L Robison; Wilburn E Reddick; Melissa M Hudson; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2019-08-12 Impact factor: 3.167
Authors: Melissa M Hudson; Matthew J Ehrhardt; Nickhill Bhakta; Malek Baassiri; Hesham Eissa; Wassim Chemaitilly; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Tara M Brinkman; James L Klosky; Kevin R Krull; Noah D Sabin; Carmen L Wilson; I-Chan Huang; Johnnie K Bass; Karen Hale; Sue Kaste; Raja B Khan; Deo Kumar Srivastava; Yutaka Yasui; Vijaya M Joshi; Saumini Srinivasan; Dennis Stokes; Mary Ellen Hoehn; Matthew Wilson; Kirsten K Ness; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-29 Impact factor: 4.254
Authors: Matthew J Ehrhardt; Daniel A Mulrooney; Chenghong Li; Malek J Baassiri; Kari Bjornard; John T Sandlund; Tara M Brinkman; I-Chan Huang; Deo Kumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Date: 2017-09-15 Impact factor: 6.860
Authors: Sunita K Patel; Leticia Miranda; Nicole Delgado; Nicolas Barreto; Anne Nolty; Natalie C Kelly; Karla Wilson; Debbie Toomey; Anna Pawlowska Journal: J Pediatr Psychol Date: 2020-09-01
Authors: Yin Ting Cheung; Michelle N Edelmann; Daniel A Mulrooney; Daniel M Green; Wassim Chemaitilly; Neena John; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-06-26 Impact factor: 4.254